<DOC>
	<DOC>NCT01209130</DOC>
	<brief_summary>This is a Phase I, multicenter, open-label, dose-escalation study of DCDT2980S administered by intravenous (IV) infusion to patients with relapsed or refractory hematologic malignancies. In addition, at selected sites, DCDT2980S will be studied in combination with rituximab.</brief_summary>
	<brief_title>A Study of the Safety and Pharmacokinetics of Escalating Doses of DCDT2980S in Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia And DCDT2980S in Combination With Rituximab in Patients With Relapsed or Refractory B-Cell Non Hodgkin's Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Leukemia, Lymphoid</mesh_term>
	<mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
	<mesh_term>Lymphoma, B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>Life expectancy of at least 12 weeks History of histologicallydocumented hematologic malignancy for which no effective standard therapy exists: indolent NHL (including Grades 13a FL; MZL [including splenic, nodal, and extranodal]; and SLL), Grade 3b FL, DLBCL, MCL, or CLL Must have at least one bidimensionally measurable lesion Prior use of any monoclonal antibody or antibodydrug conjugate within 4 weeks prior to study treatment Treatment with radiotherapy, any chemotherapeutic agent, or treatment with any other investigational anticancer agent within 2 weeks prior to of study treatment Completion of autologous stem cell transplant within 100 days prior to study treatment Prior allogeneic stem cell transplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>